Edition:
United States

Recordati Industria Chimica e Farmaceutica SpA (RECI.MI)

RECI.MI on Milan Stock Exchange

30.53EUR
11:39am EDT
Change (% chg)

€-0.44 (-1.42%)
Prev Close
€30.97
Open
€31.05
Day's High
€31.06
Day's Low
€30.53
Volume
331,014
Avg. Vol
793,284
52-wk High
€40.80
52-wk Low
€27.49

Latest Key Developments (Source: Significant Developments)

CVC In Talks Over 3 Bln Euro Stake In Recordati Pharma Business - FT
Tuesday, 19 Jun 2018 09:53am EDT 

June 19 (Reuters) - :CVC IN TALKS OVER 3 BILLION EURO STAKE IN RECORDATI PHARMA BUSINESS - FT, CITING SOURCES.  Full Article

Recordati Proposes Total Dividend Of EUR 0.85 /shr
Thursday, 15 Mar 2018 07:13am EDT 

March 15 (Reuters) - RECORDATI ::PROPOSES DIVIDEND OF EUR 0.85 PER SHARE, OF WHICH EUR 0.42 ALREADY PAID.  Full Article

Recordati FY Prelim. Net Profit Up 21.6 Pct At EUR 288.8 Mln
Thursday, 8 Feb 2018 06:24am EST 

Feb 8 (Reuters) - RECORDATI ::FY PRELIM NET REVENUES EUR 1,288.1 MILLION, UP 11.6 PERCENT YEAR ON YEAR.FY PRELIM NET PROFIT EUR 288.8 MILLION, UP 21.6 PERCENT YEAR ON YEAR.IN 2018 OBJECTIVE IS TO ACHIEVE SALES RANGING FROM € 1,350 MILLION TO € 1,370 MILLION.IN 2018 OBJECTIVE IS TO ACHIEVE EBITDA OF BETWEEN € 490 AND € 500 MILLION.IN 2018 OBJECTIVE IS TO ACHIEVE NET INCOME OF BETWEEN € 310 AND € 315 MILLION.  Full Article

Recordati Q3 net profit up at EUR ‍​72.8 mln, confirms FY targets
Thursday, 26 Oct 2017 05:49am EDT 

Oct 26 (Reuters) - RECORDATI ::Q3 NET PROFIT EUR ‍​72.8 MILLION VERSUS EUR 59.6 MILLION YEAR AGO.Q3 REVENUE EUR 313.0 ‍​MILLION VERSUS EUR 274.5 MILLION YEAR AGO.INTERIM 2017 DIVIDEND OF EUR 0.42 PER SHARE TO BE DISTRIBUTED‍​.CONFIRMS FY 2017 TARGETS.  Full Article

Recordati H1 net profit up at EUR 147.0 mln, raises FY 2017 targets
Thursday, 27 Jul 2017 05:12am EDT 

July 27 (Reuters) - RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA ::H1 REVENUE EUR 650.9 MILLION VERSUS EUR 587.9 MILLION YEAR AGO.H1 NET PROFIT EUR 147.0 MILLION VERSUS EUR 122.7 MILLION YEAR AGO.RAISES FULL YEAR 2017 TARGETS.SEES FY 2017 SALES BETWEEN € 1,290 AND € 1,300 MILLION.SEES FY 2017 OPERATING INCOME BETWEEN € 400 AND € 410 MILLION.SEES FY 2017 NET INCOME BETWEEN € 290 AND € 295 MILLION.SEES FY 2017 EBITDA BETWEEN € 450 AND € 460 MILLION.  Full Article

Recordati acquisition of rights to Astrazeneca’s metoprolol based treatments in Europe completed
Monday, 3 Jul 2017 02:13am EDT 

July 3 (Reuters) - RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA ::AGREEMENT WITH ASTRAZENECA <<>> FOR PURCHASE OF RIGHTS TO SELOKEN/SELOKEN ZOK AND ASSOCIATED LOGIMAX FIXED DOSE COMBINATION TREATMENTS IN EUROPE IS CONCLUDED.CONSIDERATION FOR ACQUISITION OF THE ASSETS OF $ 290 MILLION (€ 258 MILLION) WAS PAID AT THE CLOSING.THE AGREEMENT HAS BEEN COMPLETED WITH EXCEPTION OF ROMANIA, WHICH IS SUBJECT TO SEPARATE CLOSING.  Full Article

Recordati signs exclusive license agreement with MimeTech
Friday, 16 Jun 2017 02:44am EDT 

June 16 (Reuters) - RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA ::SIGNS EXCLUSIVE LICENSE AGREEMENT WITH MIMETECH FOR DEVELOPMENT AND COMMERCIALIZATION OF A LOW MOLECULAR WEIGHT PEPTIDOMIMETIC OF HUMAN NERVE GROWTH FACTOR (NGF) FOR TREATMENT OF NEUROTROPHIC KERATITIS.  Full Article

Recordati acquires from AstraZeneca European rights to Metoprolol based products
Monday, 22 May 2017 02:13am EDT 

May 22 (Reuters) - RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA SPA ::ACQUIRES FROM ASTRAZENECA <<>> EUROPEAN RIGHTS TO PRODUCTS BASED ON METOPROLOL.THE CONSIDERATION FOR THE ACQUISITION OF THE ASSETS IS OF $ 300 MILLION (APPROX. € 270 MILLION) AND WILL BE FUNDED BY EXISTING LIQUIDITY AND AVAILABLE CREDIT LINES.ROYALTIES FOR THE USE OF THE EXISTING PRODUCT BRANDS WILL BE DUE TO ASTRAZENECA FOR AN AGREED PERIOD.METOPROLOL SUCCINATE IS A BETA‐BLOCKER FOR THE CONTROL OF HYPERTENSION, ANGINA AND HEART FAILURE.EXISTING SALES OF THE METOPROLOL BRANDS WILL PROVIDE THE BASE TO ENTER NEW MARKETS AND COMPLETE EUROPEAN GEOGRAPHICAL FOOTPRINT.  Full Article

EU Medicines Agency recommends against approval of AB Science mastocytosis drug Masitinib
Friday, 19 May 2017 07:59am EDT 

May 19 (Reuters) - EU Medicines Agency: :EU Medicines Agency recommends approval of Valeant Pharmaceuticals Inc psoriasis drug Brodalumab.EU Medicines Agency recommends approval of Richter Gedeon and Recordati Industria Chimica E Farmaceutica SPA Cariprazine drug for bipolar mania and schizophrenia.EU Medicines Agency recommends against approval of AB Science mastocytosis drug Masitinib.  Full Article

Recordati raises FY 2017 targets
Thursday, 4 May 2017 06:49am EDT 

May 4 (Reuters) - Recordati Industria Chimica e Farmaceutica SpA ::FY 2017 targets increased: sales of around EUR 1,250 million ($1.37 billion), EBITDA of around EUR 425 million, operating income around EUR 380 million and net income around EUR 275 million.  Full Article